Co-treatment of PCSK9 inhibitors with drugs that suppress cholesterol synthesis is even more effective in reducing LDL cholesterol in hypercholesterolemia patients [23-25]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.